FDA peptide advisory vote, July 2026: what it means for BPC-157, KPV, TB-500 and more
- On 23–24 July 2026 an FDA advisory committee narrowly voted to recommend six peptides for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax.
- It voted against emideltide (DSIP).
- The vote is advisory. None of these peptides is FDA-approved, and pharmacies may not compound them until FDA completes rulemaking.
- On 14 October 2026 an FDA "Interim Access Policy for Compounding Using Certain Peptides" was sent to the White House for review. It has not been published.
- Nothing here makes research-use-only (RUO) sales of these peptides for human use lawful.
What did the FDA advisory committee vote on?
The FDA Pharmacy Compounding Advisory Committee (PCAC) met on 23 and 24 July 2026 to consider whether seven peptides should be added to the 503A bulks list, the list of bulk drug substances that licensed compounding pharmacies may use. FDA staff had recommended against all seven in briefing documents released at the end of June.
| Peptide | Committee outcome | Our profile |
|---|---|---|
| BPC-157 | Recommended (narrow vote) | BPC-157 |
| KPV | Recommended (narrow vote) | KPV |
| TB-500 | Recommended | TB-500 |
| MOTS-c | Recommended | MOTS-c |
| Epitalon | Recommended | Epitalon |
| Semax | Recommended | Semax |
| Emideltide (DSIP) | Not recommended | DSIP |
Is BPC-157 legal now?
Not in the sense most people mean. BPC-157 is still not an FDA-approved drug. The committee vote is a recommendation only: FDA must decide whether to act, publish a proposed rule, take public comments and issue a final rule before pharmacies can compound it under section 503A. Commentators estimate that process takes 6 to 18 months once FDA decides to proceed.
The same applies to KPV, TB-500, MOTS-c, Epitalon and Semax. For background on each compound, see our research peptide library.
What is the interim access policy?
On 14 October 2026 the White House Office of Information and Regulatory Affairs logged an FDA notice titled "Interim Access Policy for Compounding Using Certain Peptides". News reports, citing unnamed sources, say it would let some licensed compounding pharmacies make certain peptides, including BPC-157, under enforcement discretion while formal rules are written.
As of 27 October 2026 the text has not been published, the list of covered peptides is not public, and it has no effective date. It concerns licensed pharmacies filling prescriptions, not research chemical sellers.
What does not change
- Research-use-only sellers. FDA judges intended use from a seller's whole website. Warning letters in 2026 have cited dose calculators, injection guidance and bundled bacteriostatic water as evidence of human use.
- The UK and EU. The US vote has no effect on MHRA or EU rules. These peptides remain unlicensed medicines there.
- Sport. BPC-157 and TB-500 remain banned by WADA, and the other compounds fall under its non-approved substances class (S0).
Timeline
| Date | Event |
|---|---|
| 15 Apr 2026 | BPC-157 and Epitalon removed from FDA's Category 2 bulks list after nominations were withdrawn |
| Late Jun 2026 | FDA briefing documents recommend against all seven peptides |
| 23–24 Jul 2026 | Advisory committee recommends six peptides and rejects emideltide |
| 14 Oct 2026 | Interim access policy sent to the White House for review |
| By Feb 2027 | Next advisory review expected, covering further peptides including GHK-Cu |
We will update this page when FDA publishes a proposed rule or the interim policy.
Frequently asked questions
Did the FDA approve BPC-157 in July 2026?
No. An FDA advisory committee recommended adding BPC-157 to the 503A bulks list. That is not drug approval, and the recommendation is not binding.
Can pharmacies compound BPC-157 now?
Not under section 503A until FDA completes rulemaking, unless a published interim policy says otherwise. As of 27 October 2026 no such policy had been published.
Which peptides did the committee reject?
Emideltide, also known as delta sleep-inducing peptide (DSIP).
Does the vote affect research peptide sellers?
No. The vote concerns licensed compounding pharmacies. Sellers of research-use-only peptides who market them for human use remain subject to FDA enforcement.
Does the vote change the law in the UK or EU?
No. US decisions do not change MHRA or EU medicines law.
Sources
- NCPA: FDA advisory committee nominates six peptides for pharmacies to compound (31 Jul 2026)
- ABC News: FDA advisers narrowly vote to add 6 peptides to a drug compounding list (24 Jul 2026)
- RAPS: FDA advisory committee backs two controversial peptides
- The Hill: FDA panel votes to add peptides to permitted compounding list
- Legal500: FDA advisory committee voted yes on six peptides. Now what?
- GoodRx: Peptide FDA updates (reviewed 16 Oct 2026)